Passage Bio (PASG)
(Delayed Data from NSDQ)
$0.83 USD
0.00 (-0.31%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.83 0.00 (0.19%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PASG 0.83 0.00(-0.31%)
Will PASG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PASG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PASG
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
PASG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
Other News for PASG
Expanding Market and Promising Preclinical Results Bolster Buy Rating for Passage Bio
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Passage Bio received positive feedback in Type C meeting with FDA on PBFT02
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference